Atypical Hemolytic Uremic Syndrome Recurrence After Kidney Transplantation

Abstract

Genetic mutations of the complement alternative pathway were confirmed in half of our patients, most of those mutations are in CHF. We demonstrate that treatment or prophylaxis with eculizumab was effective in reversing or preventing aHUS whether or not genetic complement mutations were identified.